Clinical Report: A New Diagnostic Target in Insulinoma

Overview

Recent research identifies DOCK10 as a promising diagnostic marker in insulinoma, showing strong specificity for insulin-secreting tumors. This discovery could enhance the accuracy of identifying clinically active lesions, particularly in complex cases.

Background

Insulinomas are rare pancreatic neuroendocrine tumors that can lead to significant hypoglycemia due to inappropriate insulin secretion. Accurate diagnosis and localization of these tumors are challenging, especially in patients with multiple lesions. Identifying reliable biomarkers is crucial for improving diagnostic precision and treatment outcomes.

Data Highlights

No numerical data available.

Key Findings

• DOCK10 is consistently overexpressed in insulin-secreting tumor components compared to normal pancreatic tissue.
• Immunostaining for DOCK10 accurately identifies clinically active insulinoma lesions, outperforming insulin staining alone.
• Single-cell RNA sequencing reveals DOCK10 expression is enriched in tumor cell populations associated with insulin secretion.
• Reducing DOCK10 expression in insulinoma cell models decreases glucose-stimulated insulin secretion without affecting overall insulin production.
• Pharmacologic inhibition of the Cdc42 signaling pathway reduces insulin hypersecretion in cell and animal models.

Clinical Implications

The identification of DOCK10 as a diagnostic marker may improve the differentiation between insulin-secreting and non-secreting tumors, aiding in the management of insulinoma. This could be particularly beneficial in complex cases involving multiple or metastatic lesions.

Conclusion

DOCK10 presents a novel approach to enhancing diagnostic accuracy in insulinoma, potentially leading to better patient outcomes. Further research is warranted to validate its clinical utility.

References

1. Author(s)/Org, Source, Year -- Title
2. The Journal of Clinical Endocrinology & Metabolism, 2023 -- Potential Utility of Circulating MicroRNA-483 as a Biomarker for IGF-II–Associated Non–Islet Cell Tumor Hypoglycemia
3. Surgical Endoscopy, 2025 -- Surgical Enucleation for Insulinoma: A Systematic Review and Meta-Analysis of Current Evidence
4. The Journal of Clinical Endocrinology & Metabolism, 2023 -- Clinical Research in Diabetes: The Role of Biomarkers, Proteoforms, and Mass Spectrometry Techniques
5. Frontiers, 2024 -- Single center experience in localization of insulinoma by selective intraarterial calcium stimulation angiography - a case series of 15 years
6. Frontiers | Single center experience in localization of insulinoma by selective intraarterial calcium stimulation angiography - a case series of 15 years
7. Enucleation for insulinoma: consolidating evidence through systematic review and meta-analysis - PMC
8. A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Trial (RADIANT-3) of Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors: Updated Safety and Overall Survival Results - PMC
9. GENETIC SYNDROMES LINKED TO INSULINOMA AND GLUCAGONOMA | Society for Endocrinology